Chandra Bhagat Pharma Raises ₹7.26 Crore via Warrants

Chandra Bhagat Pharma Ltd has allotted 66,00,000 convertible warrants on a preferential basis to promoters and non-promoters. The allotment, approved by the board on October 22, 2026, was disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Each warrant has been issued at ₹44, including premium. The company received ₹7.26 crore as upfront consideration from the allottees. The warrants may be converted into an equal number of equity shares within 18 months of allotment. The transaction follows shareholder approval obtained at the company’s 23rd Annual General Meeting on September 1, 2026. BSE had also issued in-principle approval for the proposed preferential issue on October 12, 2026. The allotment is an important capital-raising step because conversion of the warrants could increase the company’s equity share base.

What Chandra Bhagat Pharma has allotted

The company has issued up to 66 lakh convertible warrants for cash on a preferential basis. Every warrant carries the right to subscribe to one equity share of face value ₹10. The conversion ratio is therefore 1:1. The issue price has been fixed at ₹44 per warrant, which was above the stated minimum issue price of ₹38.46 based on the relevant date of July 31, 2026. At the full issue price, the proposed warrant issue has an aggregate value of ₹29.04 crore. The company has received 25% of this value at the time of allotment. This translates to cash consideration of ₹7.26 crore. The remaining amount is payable by warrant holders when they exercise their conversion option.

Key terms of the preferential issue

Funding plan outlined by the company

Chandra Bhagat Pharma had stated in its annual report for 2025-26 that the proposed issue proceeds would be used for working capital and general corporate purposes. Of the ₹29.04 crore proposed to be raised through the warrant issue, ₹22 crore was earmarked for working capital requirements. The remaining ₹7.04 crore was earmarked for general corporate purposes. The ₹7.26 crore received at allotment represents the initial 25% payment requirement for the warrants. Further funds will arise only if and when the warrant holders choose to convert their instruments into shares. The company has not stated in the supplied disclosure that the full ₹29.04 crore has been received. Investors should therefore distinguish between the aggregate value of the issue and the upfront cash collected. The final capital raised will depend on conversion within the permitted 18-month period.

Promoter and non-promoter participation

The preferential issue has been made to both promoter and non-promoter allottees. The disclosed allotment details include 5,00,000 warrants for promoter Hemant Chandravadan Bhagat and 10,00,000 warrants for promoter Pranav Hemant Bhagat. Non-promoter Samir Ramakant Dave has been allotted 8,00,000 warrants. The company had earlier said that post-issue shareholding would be determined after the issue and conversion process. Warrant allotment itself does not immediately create equity shares. Equity dilution for existing shareholders will occur if the outstanding warrants are exercised and converted into shares. The extent of dilution will depend on the number of warrants ultimately converted. The warrant structure allows the identified investors to subscribe for shares during the 18-month exercise period.

Approvals before the allotment

The issue progressed through a series of corporate and regulatory steps. The company first proposed an increase in authorised share capital, subject to shareholder approval, alongside the preferential warrant proposal. Its shareholders approved the relevant resolutions at the 23rd AGM held on September 1, 2026. The company reported that all four resolutions received 100% support from votes polled, with no votes cast against them. A corrigendum to the AGM notice had been issued on August 20, 2026 to provide a web link to the compliance certificate related to the preferential allotment. BSE then granted in-principle approval on October 12, 2026. This approval covered the issue of 66 lakh warrants convertible into an equal number of equity shares. The board subsequently approved the allotment on October 22, 2026.

What BSE’s in-principle approval means

BSE’s in-principle approval permitted the company to proceed with the preferential issue subject to applicable requirements. It did not amount to final listing approval for the equity shares that may arise upon warrant conversion. The approval letter specified that the securities would be issued to promoters and non-promoters and that each underlying equity share would carry a face value of ₹10. The company must make the necessary listing application after allotment in line with the applicable exchange and SEBI requirements. The supplied disclosures state that the listing application is to be filed within 20 days of allotment. The process is also subject to Regulation 14 of the LODR Regulations and the relevant provisions of the SEBI ICDR Regulations. The company had stated that listing and lock-in requirements would apply under the ICDR framework. These requirements govern the securities issued through the preferential route.

Conversion window and shareholder dilution

Warrant holders have up to 18 months from allotment to exercise their conversion rights. On conversion, each warrant will result in the issue of one equity share at the predetermined price of ₹44. If all 66 lakh warrants are converted, the company will issue 66 lakh new equity shares. This would expand the outstanding equity base and dilute the percentage ownership of existing shareholders who do not participate in the issue. The actual dilution cannot be determined from the supplied information because the pre-issue paid-up equity share capital and the number of warrants ultimately converted are not provided. The company has clearly identified the potential dilution risk in the context of new shares being issued on conversion. Until conversion takes place, the warrants remain instruments carrying a future right to receive equity shares. The 18-month period provides the allottees with a defined window to complete the payment and conversion process.

Regulatory conditions for allottees

The issue is structured under the SEBI ICDR Regulations, 2018. The disclosures refer to restrictions on allottees engaging in intra-day trading or selling shares of the company before the formal allotment date. The company is required to obtain written undertakings from the allottees regarding these restrictions. Such conditions are part of the compliance framework for a preferential issue. The company also stated that the securities would be subject to applicable lock-in provisions. These requirements are designed to govern the allotment, listing and subsequent holding of securities issued through this route. The preferential issue is distinct from a public offer because it is made to identified investors rather than being offered broadly to the public. The allotment therefore follows the specific shareholder and exchange approval process set out for preferential transactions.

Why the transaction matters

The warrant allotment gives Chandra Bhagat Pharma initial cash proceeds of ₹7.26 crore while creating the possibility of further inflows upon conversion. The company has identified working capital as the principal intended use of the proposed funds, with ₹22 crore allocated for that purpose in its stated plan. The transaction also brings promoter and non-promoter participation into the capital-raising exercise. For shareholders, the key financial consideration is that 66 lakh additional shares may be created if all warrants are exercised. The issue price is fixed at ₹44, while the conversion period extends for 18 months from allotment. The company must now complete the required listing-related filings following the allotment. Further disclosures on conversions, if any, will clarify the final increase in equity capital. The October 22 allotment marks the completion of the initial funding stage of the preferential issue.

Conclusion

Chandra Bhagat Pharma has completed the allotment of 66 lakh convertible warrants at ₹44 each and received ₹7.26 crore as the required upfront consideration. The warrants can be converted into an equal number of equity shares within 18 months, potentially taking the total issue value to ₹29.04 crore. The company has stated that the proposed proceeds are intended for working capital and general corporate purposes. The next regulatory step is the required listing application after allotment, followed by any future disclosures on warrant exercise and conversion.